Table 1 Immuno-competent syngeneic murine models of glioma
From: Immunocompetent murine models for the study of glioblastoma immunotherapy
Cell line | Host | Induction | Histology | Specific and potential applications in immunotherapy | Refs |
|---|---|---|---|---|---|
P560 | VM/Dk | Spontaneous | Anaplastic Astrocytoma | • Vaccine studies (e.g. DC) | 13, 31-38 |
• Gene therapy studies (e.g. IL-2, CD70) | |||||
• Reversal of immunosuppression in glioma (e.g. TGF-β) | |||||
CT-2A | C57BL/6 | Chemical | Anaplastic Astrocytoma | • Tumor stem cells (BTSCs) | 39-63 |
• Reversal of immunosuppression in glioma (e.g. TGF-β, PTEN) | |||||
GL261 | C57BL/6 | Chemical | GBM/Ependymoblastoma | • Tumor stem cells (BTSCs) | 10, 35, 60, 64-99 |
• Vaccine studies (e.g. dendritic cells) | |||||
• Gene therapy studies (e.g. IL-2) | |||||
• Adoptive T cell, antibody, and Treg depletion studies | |||||
• Reversal of immunosuppression in glioma (e.g. TGF-β, PTEN) | |||||
GL26 | C57BL/6 | Chemical | GBM/Ependymoblastoma | • Vaccine studies (e.g. dendritic cells) | 64, 66, 100-105 |
• Gene therapy studies (e.g. IL-12) | |||||
• Treg depletion studies | |||||
• Chemo-immunotherapy | |||||
4C8 | B6D2F1 | Transgenic | Oligodendroglioma, Astrocytoma | • Vaccine studies (e.g. HSV) | 106-110 |
• Gene therapy studies (e.g. plasmids) |